AAK1 and COVID-19: In an attempt to manage COVID-19, Jakinibs caught the attention of researchers when baricitinib potential was identified using artificial intelligence in its ability to bind with high affinity to two human numb associated kinases, namely, AP2-associated protein kinase-1 and cyclic G-associated kinase (GAK), which regulates clathrin-mediated endocytosis.